Evidence map›Paper›PMID 31166958›Full record

ArticlePloS one2019

Association between MICA polymorphisms, s-MICA levels, and pancreatic cancer risk in a population-based case-control study.

Guillaume Onyeaghala, John Lane, Nathan Pankratz, Heather H Nelson, Bharat Thyagarajan, Bruce Walcheck, Kristin E Anderson, Anna E Prizment

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Associations between MICA and MICB Genetic Variants, Protein Levels, and Colorectal Cancer: Atherosclerosis Risk in Communities (ARIC).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  5. Study of the association between aClinical and experimental hepatology · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. High-ThroughputFrontiers in immunology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Guillaume OnyeaghalaDivision of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, United States of America.ORCID 0000-0001-8090-5640
John LaneUniversity of Minnesota Masonic Cancer Center, Minneapolis, MN, United States of America.
Nathan PankratzUniversity of Minnesota Masonic Cancer Center, Minneapolis, MN, United States of America.
Heather H NelsonDivision of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, United States of America.
Bharat ThyagarajanUniversity of Minnesota Masonic Cancer Center, Minneapolis, MN, United States of America.
Bruce WalcheckUniversity of Minnesota Masonic Cancer Center, Minneapolis, MN, United States of America.
Kristin E AndersonDivision of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, United States of America.
Anna E PrizmentDivision of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, United States of America.ORCID 0000-0001-5924-6871
University of Minnesota · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Institutional Career Development CoreKL2TR002492 · NCATS · UNIVERSITY OF MINNESOTA · PI INGBAR, DAVID H · 2018 to 2022
$6.3M
Expression of recombinant Fc receptors by engineered NK cells to enhance cancer cell killingR01CA203348 · NCI · UNIVERSITY OF MINNESOTA · PI WALCHECK, BRUCE K, WU, JIANMING · 2016 to 2025
$4.4M
NCATS NIH HHS KL2 TR002492NCATS NIH HHS UL1 TR000114NCATS NIH HHS UL1 TR002494NCI NIH HHS R01 CA203348
6 · The paper itself

Abstract

backgroundPancreatic tumor cells may avoid immune surveillance by releasing the transmembrane major histocompatibility complex class I chain-related A (MICA) protein in soluble form (s-MICA). We hypothesized that the presence of the A5.1 polymorphism in the MICA gene, which encodes a truncated MICA protein, is associated with higher s-MICA levels and increased pancreatic cancer risk.

methodsMICA alleles and s-MICA levels were measured in 121 pancreatic cancer cases and 419 controls. General linear regression with a log transformation assessed geometric means of s-MICA levels across MICA alleles. Unconditional logistic regression was used to calculate the odds ratio (OR) and 95% confidence intervals (CI) for pancreatic cancer associated with MICA alleles.

resultsAfter multivariate adjustment, participants with at least one copy of the A5.1 allele versus no A5.1 allele had 1.35 (95% CI: 1.05-1.74) times greater s-MICA levels (1.65 times higher for cases and 1.28, for controls) and increased risk of pancreatic cancer (OR = 1.91, 95% CI: 1.05-3.48).

conclusionsOur study suggests higher risk of pancreatic cancer among those with the MICA A5.1 polymorphism, which may be explained by an increase in s-MICA secretion and impaired immune response. IMPACT: These findings provide further evidence at the genetic and molecular level of the important role of MICA in pancreatic cancer development, and may have important implications with regards to pancreatic cancer screening.

Indexed as

Genetic Predisposition to DiseasePolymorphism, GeneticAgedCase-Control StudiesFemaleHistocompatibility Antigens Class IHumansMaleMicrosatellite RepeatsPancreatic NeoplasmsRisk FactorsSolubilityHistocompatibility Antigens Class IMHC class I-related chain A

Identifiers

PMID31166958
PMCPMC6550421
OpenAlexW2948850940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.